Literature DB >> 35693405

Impact of pathological response after preoperative transcatheter arterial chemoembolization (TACE) on incidences of microvascular invasion and early tumor recurrence in hepatocellular carcinoma: a multicenter propensity score matching analysis.

Yun Yang1, Zheng Dang2, Peng Lu3, Youwen Qian4, Kongying Lin5, Zeya Pan1, Wan Yee Lau1,6, Weiping Zhou1,7,8.   

Abstract

Background: To study the influence of pathological responses (PR) after transcatheter arterial chemoembolization (TACE) on incidences of microvascular invasion (MVI) and early recurrence in hepatocellular carcinoma (HCC) patients.
Methods: Between 2013 to 2015, consecutive HCC patients who underwent liver resection with "curative" intent at three hospitals were enrolled in this study. Patients with different areas of PR after preoperative TACE were compared with those without preoperative TACE on the incidences of MVI, early recurrence rates and patterns of recurrence before and after propensity score matching (PSM).
Results: Of 1,970 patients, 737 patients who received preoperative TACE were divided into three groups according to the areas of PR: ≥90% (n=226), 60-90% (n=447), and <60% (n=64). PR ≥90% was an independent protective factor of incidences of MVI [odds ratio (OR), 0.144; 95% confidence interval (CI), 0.082-0.245, P<0.001) and early recurrence (HR, 0.742; 95% CI, 0.561-0.963, P=0.032); while PR<60% was an independent risk factor of incidences of MVI (OR, 6.076; 95% CI, 3.004-11.728, P<0.001) and early recurrence (HR, 1.428; 95% CI, 1.095-1.929; P=0.009). Furthermore, patients with PR <60% were significantly more likely to develop multiple intrahepatic recurrences involving multiple hepatic segments when compared with patients without preoperative TACE. Conclusions: This study indicated the area of PR after TACE was closely associated with the incidences of MVI and early tumor recurrence. Patients with PR <60% were at significantly higher risks of having more MVI, early and multiple tumor recurrences. 2022 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); early recurrence; microvascular invasion (MVI); pathological response; transcatheter arterial chemoembolization (TACE)

Year:  2022        PMID: 35693405      PMCID: PMC9186194          DOI: 10.21037/hbsn-20-700

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   8.265


  45 in total

1.  Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis.

Authors:  Tian Yang; Jun-Hua Lu; Wan Yee Lau; Tian-Yi Zhang; Han Zhang; Yi-Nan Shen; Kutaiba Alshebeeb; Meng-Chao Wu; Myron Schwartz; Feng Shen
Journal:  J Hepatol       Date:  2015-10-24       Impact factor: 25.083

2.  HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma.

Authors:  Won Sohn; Yong-Han Paik; Jong Man Kim; Choon Hyuk Kwon; Jae Won Joh; Ju Yeon Cho; Geum-Youn Gwak; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  Ann Surg Oncol       Date:  2014-03-12       Impact factor: 5.344

3.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

4.  Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma.

Authors:  Xun Xu; Hai-Long Zhang; Qiu-Ping Liu; Shu-Wen Sun; Jing Zhang; Fei-Peng Zhu; Guang Yang; Xu Yan; Yu-Dong Zhang; Xi-Sheng Liu
Journal:  J Hepatol       Date:  2019-03-13       Impact factor: 25.083

5.  Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria.

Authors:  Kheng-Choon Lim; Pierce Kah-Hoe Chow; John C Allen; Ghim-Song Chia; Miaoshan Lim; Peng-Chung Cheow; Alexander Y F Chung; London L P Ooi; Say-Beng Tan
Journal:  Ann Surg       Date:  2011-07       Impact factor: 12.969

6.  Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma.

Authors:  Zheng Li; Zhengqing Lei; Yong Xia; Jun Li; Kui Wang; Han Zhang; Xuying Wan; Tian Yang; Weiping Zhou; Mengchao Wu; Timothy M Pawlik; Wan Yee Lau; Feng Shen
Journal:  JAMA Surg       Date:  2018-10-17       Impact factor: 14.766

7.  Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.

Authors:  Adriana Sergio; Chiara Cristofori; Romilda Cardin; Giorgio Pivetta; Roberto Ragazzi; Anna Baldan; Lisa Girardi; Umberto Cillo; Patrizia Burra; Anna Giacomin; Fabio Farinati
Journal:  Am J Gastroenterol       Date:  2008-01-02       Impact factor: 10.864

8.  Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.

Authors:  Shuji Sumie; Ryoko Kuromatsu; Koji Okuda; Eiji Ando; Akio Takata; Nobuyoshi Fukushima; Yasutomo Watanabe; Masamichi Kojiro; Michio Sata
Journal:  Ann Surg Oncol       Date:  2008-03-07       Impact factor: 5.344

9.  A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma.

Authors:  Sasan Roayaie; Iris N Blume; Swan N Thung; Maria Guido; Maria-Isabel Fiel; Spiros Hiotis; Daniel M Labow; Josep M Llovet; Myron E Schwartz
Journal:  Gastroenterology       Date:  2009-06-12       Impact factor: 22.682

10.  Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.

Authors:  Mingsheng Huang; Long Wang; Junwei Chen; Mingjun Bai; Churen Zhou; Sujuan Liu; Qu Lin
Journal:  Int J Oncol       Date:  2016-03-04       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.